ECSP088733A - Anticuerpos anti-5t4 y usos de los mismos - Google Patents

Anticuerpos anti-5t4 y usos de los mismos

Info

Publication number
ECSP088733A
ECSP088733A EC2008008733A ECSP088733A ECSP088733A EC SP088733 A ECSP088733 A EC SP088733A EC 2008008733 A EC2008008733 A EC 2008008733A EC SP088733 A ECSP088733 A EC SP088733A EC SP088733 A ECSP088733 A EC SP088733A
Authority
EC
Ecuador
Prior art keywords
antibodies
same
antibody
preparing
methods
Prior art date
Application number
EC2008008733A
Other languages
English (en)
Inventor
Arthur Kunz
Erwin Raymond Arsene Boghaert
Philip Ross Hamann
Nitin Krishnaji Damle
Davinder S Gill
Kimberly A Marquette
Lioudmila Tchistiakova
Kiran Khandke
Kodangattil Sreekumar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088733(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088733A publication Critical patent/ECSP088733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpos anti-5T4, conjugados de anticuerpo anti-5T4/fármaco, y métodos para preparar y usar los mismos.
EC2008008733A 2006-03-10 2008-09-10 Anticuerpos anti-5t4 y usos de los mismos ECSP088733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78134606P 2006-03-10 2006-03-10
US89124807P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
ECSP088733A true ECSP088733A (es) 2008-10-31

Family

ID=38445207

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008733A ECSP088733A (es) 2006-03-10 2008-09-10 Anticuerpos anti-5t4 y usos de los mismos

Country Status (29)

Country Link
US (5) US8044178B2 (es)
EP (3) EP2368914B1 (es)
JP (1) JP5523824B2 (es)
KR (2) KR101443752B1 (es)
CN (1) CN101437850B (es)
AR (1) AR059809A1 (es)
AU (1) AU2007226696C1 (es)
BR (1) BRPI0708771B8 (es)
CA (1) CA2645097C (es)
CR (1) CR10273A (es)
DK (2) DK1994055T3 (es)
EC (1) ECSP088733A (es)
ES (2) ES2498517T3 (es)
GT (1) GT200800181A (es)
IL (2) IL193986A (es)
MX (1) MX2008011492A (es)
MY (1) MY148763A (es)
NO (1) NO20083891L (es)
NZ (2) NZ571208A (es)
PA (1) PA8718601A1 (es)
PE (1) PE20080119A1 (es)
PL (1) PL1994055T3 (es)
PT (1) PT1994055E (es)
SA (1) SA07280101B1 (es)
SG (1) SG170091A1 (es)
SI (1) SI1994055T1 (es)
TW (2) TWI421257B (es)
WO (1) WO2007106744A2 (es)
ZA (1) ZA200808075B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978985A2 (en) * 2005-12-23 2008-10-15 Board Of Regents Of The University Of Texas System Anti-hyperproliferative therapies targeting hdgf
PT1994055E (pt) * 2006-03-10 2014-09-15 Wyeth Llc Anticorpos anti-5t4 e utilizações dos mesmos
WO2008027986A2 (en) 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
ES2405605T3 (es) 2009-03-27 2013-05-31 Wyeth Llc Células iniciadoras de tumores y procedimientos de uso de las mismas
GB0918383D0 (en) * 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
US9592331B2 (en) 2011-02-07 2017-03-14 Aggamin Llc Methods and systems for treating eclampsia or pre-eclampsia
ES2596194T3 (es) * 2011-04-01 2017-01-05 Wyeth Llc Conjugados de anticuerpo-fármaco
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
RU2646498C2 (ru) 2012-01-24 2018-03-05 Пфайзер Инк. Способы детектирования 5Т4-положительных циркулирующих опухолевых клеток и способы диагностики 5Т4-положительного рака у млекопитающего
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
WO2014137931A1 (en) * 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
EP2968536B1 (en) * 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
US20160304617A1 (en) * 2013-06-17 2016-10-20 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
AR098221A1 (es) 2013-11-04 2016-05-18 Pfizer Conjugados de anticuerpo anti-efna4-fármaco
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
MX374342B (es) 2014-05-22 2025-03-06 Byondis Bv Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes.
SG10201913324PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
ES2715413T3 (es) 2014-07-29 2019-06-04 Cellectis Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
EP3194432B1 (en) 2014-07-31 2019-04-10 Cellectis Ror1 specific multi-chain chimeric antigen receptor
JP6810685B2 (ja) * 2014-09-04 2021-01-06 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のための栄養膜糖タンパク質（５ｔ４、ｔｐｂｇ）特異的キメラ抗原受容体
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
EP3298046B1 (en) 2015-05-20 2025-02-12 Cellectis Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
RU2736720C2 (ru) * 2015-11-24 2020-11-19 Байондис Б.В. Антитела против 5t4 и конъюгаты антитело-лекарственное средство
CN106916227B (zh) * 2015-12-24 2019-12-13 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
AU2017299581B2 (en) * 2016-07-20 2024-05-23 EyePoint Pharmaceuticals, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
CN108084265B (zh) * 2016-11-23 2021-07-02 复旦大学 特异性结合人的5t4抗原的全人源单域抗体及其应用
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CN108285487B (zh) * 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
KR20230166145A (ko) * 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
JP7305549B2 (ja) * 2017-04-05 2023-07-10 エックスディーシーエクスプローラー （シャンハイ） カンパニー リミテッド ヒト化抗ｔｐｂｇ抗体およびその製造方法、その複合体および使用
KR20240165484A (ko) 2017-04-11 2024-11-22 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
US20200165351A1 (en) * 2017-06-06 2020-05-28 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
WO2019016402A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN108187065B (zh) * 2017-12-29 2023-04-28 广东众生药业股份有限公司 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
WO2019136167A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
EP3873534A1 (en) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
EP4028424A1 (en) 2019-09-12 2022-07-20 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Cd28 single domain antibodies and multivalent and multispecific constructs thereof
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
US20220288244A1 (en) * 2020-10-22 2022-09-15 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US20220251239A1 (en) * 2020-10-22 2022-08-11 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
US20240067729A1 (en) * 2021-01-06 2024-02-29 Palleon Pharmaceuticals Inc. Anti-pd-l1 antibodies and fusion proteins thereof
EP4482876A1 (en) * 2022-02-21 2025-01-01 Concept to Medicine Biotech Co., Ltd. Anti-5t4 antibodies and uses thereof
AU2023350248A1 (en) 2022-09-30 2025-04-17 Shanghai De Novo Pharmatech Co., Ltd. Benzazepine derivative, conjugate containing same, and use thereof
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
CN116715773B (zh) * 2023-02-28 2024-03-01 星奕昂(上海)生物科技有限公司 一种靶向5t4的抗体及其应用
KR20250158033A (ko) * 2023-03-08 2025-11-05 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-5t4 항체 및 이의 용도
WO2024197151A2 (en) * 2023-03-22 2024-09-26 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
AU2024252256A1 (en) * 2023-04-03 2025-11-06 Sound Biopharmaceuticals Co. Ltd. Anti-5t4 antibody and use thereof
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5037651A (en) 1987-01-30 1991-08-06 American Cyanamid Company Dihydro derivatives of LL-E33288 antibiotics
US5108912A (en) 1987-01-30 1992-04-28 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5869053A (en) 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
WO1989007947A1 (en) * 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1997026885A1 (en) 1996-01-23 1997-07-31 The General Hospital Corporation Doing Business As Massachusetts General Hospital Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
PT1012259E (pt) 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
WO2000029428A2 (en) 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
GB2378704B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Uses of 5t4 antigen
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1396543A3 (en) * 1999-07-08 2004-03-31 Research Association for Biotechnology Primers for synthesizing full length cDNA clones and their use
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
CA2422155A1 (en) 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
EP1347994A2 (en) * 2000-11-13 2003-10-01 Oxford Biomedica (UK) Limited Canine and feline tumour-associated antigen 5t4
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
PL224001B1 (pl) 2002-05-02 2016-11-30 Wyeth Corp Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CA2571743A1 (en) 2004-06-30 2006-01-12 International Bioimmune Systems, Inc. Humanized monoclonal antibody 31.1 as an anticancer agent
RU2007108716A (ru) 2004-09-10 2008-10-20 Вайет (Us) Гуманизированные антитела к антигену 5т4 и конъюгаты гуманизированного антитела к антигену 5т4 с калихеамицином
US20090285806A1 (en) * 2004-10-05 2009-11-19 Martin Sinacore Methods and compositions for improving recombinant protein production
PT1994055E (pt) * 2006-03-10 2014-09-15 Wyeth Llc Anticorpos anti-5t4 e utilizações dos mesmos
NO3056203T3 (es) 2010-04-21 2018-05-12
ES2596194T3 (es) * 2011-04-01 2017-01-05 Wyeth Llc Conjugados de anticuerpo-fármaco

Also Published As

Publication number Publication date
US9902771B2 (en) 2018-02-27
US20140308302A1 (en) 2014-10-16
KR20080106345A (ko) 2008-12-04
PA8718601A1 (es) 2009-05-15
JP2009529578A (ja) 2009-08-20
SG170091A1 (en) 2011-04-29
TW200804424A (en) 2008-01-16
US20070231333A1 (en) 2007-10-04
JP5523824B2 (ja) 2014-06-18
SI1994055T1 (sl) 2014-08-29
AU2007226696B2 (en) 2013-08-29
EP1994055B1 (en) 2014-07-02
KR101443752B1 (ko) 2014-09-26
US8759495B2 (en) 2014-06-24
KR101264216B1 (ko) 2013-05-31
EP2368914B1 (en) 2019-01-02
RU2008137074A (ru) 2010-04-20
BRPI0708771B8 (pt) 2021-05-25
HK1121473A1 (en) 2009-04-24
US8044178B2 (en) 2011-10-25
ES2498517T3 (es) 2014-09-24
WO2007106744A2 (en) 2007-09-20
BRPI0708771A2 (pt) 2011-06-14
NZ596295A (en) 2013-01-25
US20160185859A1 (en) 2016-06-30
ES2712942T3 (es) 2019-05-16
TWI409277B (zh) 2013-09-21
CR10273A (es) 2008-11-26
EP1994055A2 (en) 2008-11-26
WO2007106744A3 (en) 2007-11-29
CN101437850A (zh) 2009-05-20
PL1994055T3 (pl) 2015-02-27
BRPI0708771B1 (pt) 2019-10-22
WO2007106744A8 (en) 2008-10-02
CN101437850B (zh) 2013-10-09
IL240245A0 (en) 2015-09-24
PT1994055E (pt) 2014-09-15
NO20083891L (no) 2008-12-03
CA2645097C (en) 2019-09-17
TWI421257B (zh) 2014-01-01
MY148763A (en) 2013-05-31
US20120064600A1 (en) 2012-03-15
SA07280101B1 (ar) 2011-10-03
TW201335189A (zh) 2013-09-01
IL193986A (en) 2015-08-31
MX2008011492A (es) 2008-09-22
EP3539989A1 (en) 2019-09-18
US20180162937A1 (en) 2018-06-14
KR20130018980A (ko) 2013-02-25
EP2368914A1 (en) 2011-09-28
IL193986A0 (en) 2011-08-01
DK1994055T3 (da) 2014-08-25
ZA200808075B (en) 2012-03-28
PE20080119A1 (es) 2008-03-04
NZ571208A (en) 2011-12-22
AR059809A1 (es) 2008-04-30
GT200800181A (es) 2010-05-25
IL240245A (en) 2017-05-29
CA2645097A1 (en) 2007-09-20
AU2007226696C1 (en) 2016-02-04
DK2368914T3 (en) 2019-03-04
AU2007226696A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
CR8958A (es) Anticuerpos Anti-5T4 humanizados y conjugados de anticuerpos anti-5T4/caliqueamicina
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
BRPI0510674A (pt) variantes fc otimizadas
CU20120095A7 (es) Antagonistas de pcsk9
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
CR10612A (es) Anticuerpo especifico prlr y sus usos
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
BRPI0821211A2 (pt) Anticorpo anti-humano cd34 humanizado, o método de preparação e usos do mesmo.
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
TR201902670T4 (tr) Anti-5t4 antikorları ve bunların kullanımları.
CR20140126A (es) Anticuerpos anti-tat226 e inmunoconjugados